ClinicalTrials.Veeva

Menu

Differential Immune Effects of Natalizumab

C

Cantonal Hospital of St. Gallen

Status

Completed

Conditions

Multiple Sclerosis, Relapsing Remitting

Study type

Observational

Funder types

Other

Identifiers

NCT00859482
Ntz-Tregs1

Details and patient eligibility

About

Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade of VLA-4 with natalizumab may not only interfere with autoimmunological processes but also with central nervous system (CNS) immune surveillance.

Full description

Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+ regulatory T cells (Tregs).

Enrollment

27 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • relapsing remitting MS
  • indication for natalizumab treatment

Exclusion criteria

  • other disease modifying agents within 2 weeks

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems